Intelligent Investor

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.120

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$49 Application for quotation of securities - SPL 15 Nov 2023 1:58PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Notice of Annual General Meeting 2023 - Clarification 15 Nov 2023 9:22AM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Starpharma Presents at Bell Potter Conference 14 Nov 2023 1:09PM $0.138 $0.120 $0.135 fallen by 12.73%
$49 Application for quotation of securities - SPL 10 Nov 2023 1:59PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Starpharma announces new CEO, Ms Cheryl Maley 10 Nov 2023 9:33AM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Notification regarding unquoted securities - SPL 6 Nov 2023 1:31PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2023 9:45AM $0.135 $0.120 $0.135 fallen by 11.11%
$49 Notice of Annual General Meeting/Proxy Form 27 Oct 2023 1:25PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 SPL to present DEP radiotheranostics at Wilsons Conference 26 Oct 2023 9:26AM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Starpharma receives $7.2 million R&D Tax Incentive refund 23 Oct 2023 9:40AM $0.130 $0.120 $0.135 fallen by 7.69%
$49 Ceasing to be a substantial holder 23 Oct 2023 8:11AM $0.130 $0.120 $0.135 fallen by 7.69%
$49 Change in substantial holding 20 Oct 2023 8:17AM $0.130 $0.120 $0.135 fallen by 7.69%
$49 Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer 18 Oct 2023 10:18AM $0.138 $0.120 $0.135 fallen by 12.73%
$49 DEP irinotecan IO/PARP combination data presented at AACR 16 Oct 2023 11:05AM $0.150 $0.120 $0.135 fallen by 20%
$49 DEP theranostic presented at international oncology meeting 16 Oct 2023 10:18AM $0.135 $0.120 $0.135 fallen by 11.11%
$49 DEP irinotecan clinical data presented at AACR meeting 16 Oct 2023 10:02AM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Ceasing to be a substantial holder 16 Oct 2023 8:07AM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Application for quotation of securities - SPL 9 Oct 2023 2:05PM $0.135 $0.120 $0.135 fallen by 11.11%
$49 Change in Director's Interest Notice - J Fairley 6 Oct 2023 2:16PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 Notification of cessation of securities - SPL 6 Oct 2023 2:10PM $0.140 $0.120 $0.135 fallen by 14.29%
$49 2023 Annual General Meeting Date 2 Oct 2023 9:06AM $0.165 $0.120 $0.135 fallen by 27.27%
$49 Ceasing to be a substantial holder 29 Sep 2023 5:24PM $0.165 $0.120 $0.135 fallen by 27.27%
$49 DEP irinotecan combination data presentation 27 Sep 2023 8:58AM $0.160 $0.120 $0.135 fallen by 25%
$49 VIRALEZ UK COVID-19 Clinical Study Completes Recruitment 25 Sep 2023 9:55AM $0.150 $0.120 $0.135 fallen by 20%
$49 Change in substantial holding 20 Sep 2023 2:31PM $0.155 $0.120 $0.135 fallen by 22.58%

26 - 50 of 756 results

Page 2 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.